Impact of Volume of Local Anesthetic Injected for Adductor Canal Block on Recovery Profile and Block Characteristics Following Total Knee Arthroplasty.
Phase: NA
Conditions: Arthroplasty, Replacement, Knee, Pain, Postoperative
Sponsor: University of Wisconsin, Madison

Impact of volume of local anesthetic injected for 
adductor canal block on recovery profile and block 
characteristics following total knee arthroplasty. 
 
 
 
University of Wisconsin – Madison 
School of Medicine and Public Health 
Department of Anesthesiology 
 
 
 
 
 

Adductor Canal TKA | Protocol (version date: 09-JUL-2014) 
page 2 of 27 
Adductor Canal for TKA Protocol 
 
Impact of volume of local anesthetic injected for adductor canal block on recovery profile and block 
characteristics following total knee arthroplasty. 
 
 
 
Principal Investigators 
Kristopher Schroeder, MD 
Department of Anesthesiology 
 
John Heiner, MD 
Department of Orthopedics and Rehabilitation 
 
Co-Investigators 
Mark Leibel, MD 
Colby Parks, MD 
Elizabeth Wilson, MD 
Tamara Chambers, RN MS 
Department of Anesthesiology 
 
Richard Illgen, MD 
Department of Orthopedics and Rehabilitation 
 
Andrew Peterson, Physical Therapist 
Szymon Wozniczka, Physical Therapist 
Department of Rehabilitation-Medical/Surgical 
 
 
Original Version Date: July 9, 2014 
Revised June 8, 2016 
 
 

 
3 
Investigator's Agreement 
1. I have read this protocol and agree to conduct this trial in accordance with Good Clinical Practice 
(GCP), all stipulations of the protocol, the Declaration of Helsinki, and applicable regulatory 
requirements as stated by my human subjects testing oversight body [e.g., independent ethics 
committee (IEC) or institutional review board (IRB)]. 
2. I will personally conduct or supervise the described investigation(s). This includes informing all 
associates, colleagues, and employees assisting in the conduct of the study about their 
obligations in meeting the above commitments. 
3. I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol. 
4. I agree that all electronic signatures will be considered the equivalent of a handwritten 
signature and will be legally binding. 
 
Protocol Title: Impact of volume of local anesthetic injected for adductor canal block on recovery 
profile and block characteristics following total knee arthroplasty. 
Version Number: V1.0 
Version Date: January 21, 2015 
 
 
 
 
 
10/20/2014 
Signature of Principal Investigator 
 
Date 
 
Kristopher Schroeder, MD 
 
 
Name of Principal Investigator (printed or typed) 
 
 
 
 

 
4 
Summary 
 
Total knee arthroplasty (TKA) can be associated with a large amount of postoperative pain.  This pain 
can oftentimes be severe enough to limit participation in physical therapy and ultimately delay 
discharge resulting in increased cost.  Several strategies have been developed in an effort to decrease 
postoperative pain following TKA while maintaining lower extremity strength and maximizing 
participation in physical therapy.  Recently, adductor canal blockade has gained popularity as it is 
reported to provide analgesia to the anterior knee without resulting in significant quadriceps muscle 
weakness.  However, few studies have carefully evaluated the impact of volume of injection of local 
anesthetic into the adductor canal on motor weakness or pain control.  The ability to achieve similar 
pain control with decreased volumes of local anesthetic would allow the surgery team to apply more 
local anesthetic to posterior knee structures.  Decreased volumes of local anesthetic may also be 
associated with a decreased risk of local anesthetic toxicity.  This study aims to carefully evaluate this 
relationship using a physical therapy evaluation method that relies on both motor strength and pain 
control.  In addition, we hope to carefully evaluate motor strength using a novel method of strength 
measurement in an effort to further evaluate the impact of volume of injection of local anesthetic into 
the adductor canal on motor strength.   
 
 
 

 
5 
Table of contents 
 
List of abbreviations and definitions ........................................................................................................... 7 
1. Introduction ............................................................................................................................................. 8 
1.1 Background ........................................................................................................................................ 8 
1.2 Rationale and hypothesis .................................................................................................................. 9 
2. Objectives ................................................................................................................................................ 9 
2.1 Primary outcome and endpoint ........................................................................................................ 9 
2.2 Secondary outcomes and endpoints ................................................................................................. 9 
3. Study design ........................................................................................................................................... 10 
4. Study population ................................................................................................................................... 10 
4.1 Inclusion criteria .............................................................................................................................. 10 
4.2 Exclusion criteria ............................................................................................................................. 10 
4.3 Protected populations ..................................................................................................................... 11 
5. Trial interventions .................................................................................................................................. 11 
5.3 Allocation to intervention ............................................................................................................... 11 
6. Subject recruitment and consent .......................................................................................................... 12 
6.1 Subject identification ...................................................................................................................... 12 
6.3 Recruitment and consent ................................................................................................................ 12 
7. Activities and measurements ................................................................................................................ 12 
7.3 Data entry ........................................................................................................................................ 14 
7.4 Subject withdrawals ........................................................................................................................ 15 
8. Data analysis and statistical considerations .......................................................................................... 15 
8.1 Sample size determination .............................................................................................................. 16 
9. Risks and benefits of trial participation ................................................................................................. 16 
9.1 Potential risks .................................................................................................................................. 16 
9.2 Mitigation of potential risks ............................................................................................................ 16 
9.3 Potential benefits and risk-to-benefit ratio ..................................................................................... 17 
10. Adverse events and unanticipated problems ...................................................................................... 17 
10.1 Adverse event definitions .............................................................................................................. 17 
10.2 Severity assessment ...................................................................................................................... 18 
10.3 Causality assessment ..................................................................................................................... 18 
10.4 Procedures for recording and reporting adverse events .............................................................. 18 
10.5 Other reportable events ................................................................................................................ 18 
11. Trial safety monitoring ......................................................................................................................... 19 
11.2 Data Safety Monitoring Committee .............................................................................................. 19 
12. Administrative requirements ............................................................................................................... 20 
12.1 Good clinical practice .................................................................................................................... 20 
12.2 Data quality assurance .................................................................................................................. 20 
12.4 Study monitoring ........................................................................................................................... 20 
12.5 Ethical consideration ..................................................................................................................... 20 
12.6 Patient confidentiality ................................................................................................................... 20 
12.7 Investigator compliance ................................................................................................................ 20 
12.8 Subject cost and payment ............................................................................................................. 21 
13. Funding sources ................................................................................................................................... 21 
References ................................................................................................................................................. 21 

 
6 
Schedule of activities 
 
 
Screening 
Visit 1 
Procedure 
Visit 2 
Post-
Adductor 
Block 
Visit 3 
PACU 
Visit 4 
24-hours 
Post-op 
Visit 5 
 
48-hours 
Post-op 
Visit 6 
Window 
Up to 60 
days 
before 
surgery 
Morning 
of Surgery 
15 
minutes 
after 
adductor 
block 
placed +/- 
10 mins 
Following 
surgical 
procedure 
24 hours 
post-op 
+/- 6 
hours 
48 hours 
post-op 
+/- 6 
hours 
Screening and 
Eligibility 
X 
X 
 
 
 
 
Informed Consent 
X 
X 
 
 
 
 
Demographics 
X 
X 
 
 
 
 
Medical History 
X 
X 
 
 
 
 
Quadricep motor 
strength and 
adductor strength 
assessment (Kiio 
sensor) 
 
X 
X 
 
 
 
Sensory Leg Exam1 
 
X 
X 
 
 
 
Questionnaires and 
Scores2 
SOC 
SOC 
 
 
 
 
Pain Questionnaire3 
 
 
 
X 
X 
X 
Physical Therapy 
Assessment and 
Walk Test4 
 
 
 
 
X 
X 
Concomitant 
Medications5 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
 
X 
1Temperature and Sensation will be examined using a pinprick and cold sensory technique 
2 SF12 mental component and physical component, WOMAC and Knee Society Score, UCLA activity score, range of motion (and 
degree of varus/valgus deformity will be collected 
3 Pain at rest, pain with activity, opioid consumption, nausea, pain disturbing sleep, location of most severe pain and 
satisfaction with regional anesthesia technique will be assessed 
4 Pain with physical therapy, quadriceps strength, passive flexion/extension range of motion, postoperative quadriceps 
strength, postoperative adductor strength, and 10 meter walk test (gait velocity) using Kiio sensor 
3 Medications that are taken at home regularly and prior to arrival on the day of surgery, surgery premedication, and all 
medications for nausea and pain will be recorded. 

 
7 
 List of abbreviations and definitions  
 
AE 
 
Adverse event 
CFNB  
Continuous Femoral Nerve Blockade 
CACNB 
Continuous Adductor Canal Nerve Blockade 
DSMC 
Data Safety Monitoring Committee 
PACU  
Post-Anesthesia Care Unit 
POD 
Post-Operative Day 
SAE 
Serious Adverse Event 
SSFNB 
Single Shot Femoral Nerve Block 
SSACNB 
Single Shot Adductor Canal Nerve Block 
TKA 
 
Total Knee Arthroplasty 
 

 
8 
1. Introduction 
1.1 Background 
Postoperative analgesia for total knee arthroplasty (TKA) is incredibly important as it allows for effective 
physical therapy and ultimately ensures proper function of the implanted joint hardware.  
Unfortunately, TKA is oftentimes associated with pain severe enough to limit participation in physical 
therapy which can ultimately result in prolonged hospitalizations and perhaps decreased joint function.  
A number of strategies have been reported to decrease the pain associated with TKA.  Opioids are 
commonly utilized but they can be associated with a number of potential side effects including nausea, 
itching, respiratory depression, tolerance and the potential for abuse.  Epidural analgesia has been 
utilized for postoperative analgesia but this strategy requires urinary catheterization (potential source of 
increased incidence of urinary tract infections), causes significant vasodilation with resulting 
hypotension and can cause bilateral lower extremity weakness that can undermine efforts at early 
physical therapy and rehabilitation.  Femoral nerve blockade and femoral nerve catheters have the 
potential to decrease pain in the anterior knee but use of this technique is limited by incomplete 
analgesia and quadriceps motor weakness.  Some groups have advocated for the substitution or 
addition of sciatic or obturator nerve blocks to femoral nerve blockade but this is at the expense of 
increased lower extremity weakness and little potential clinical benefit.1-5  
 
In an effort to balance the need for effective postoperative analgesia with the need to maintain lower 
extremity muscle strength for active participation in physical therapy, a number of groups have begun to 
evaluate the adductor canal block.  The adductor canal is located in the middle 1/3 of the thigh and 
includes the saphenous nerve and nerve to the vastus medialis.  The primary advantage to adductor 
canal blockade versus femoral nerve blockade is a potential sparing of the nerves to the quadriceps 
muscle and therefore preservation of lower extremity motor strength.6-8  Kwofie et al reported in a 
study of 16 volunteers that there was no change in quadriceps strength or hip adduction following the 
injection of 15 ml of local anesthetic.  This is interesting as the obturator nerve is reported to travel 
within the adductor canal and is responsible for hip adduction.  Kwofie et al also reported that SSACNB 
resulted in significantly decreased impairments with balance compared to a SSFNB.9   
 
To this point, the majority of studies evaluating adductor canal blockade have focused on continuous 
techniques and little has been done to evaluate single shot techniques.  Continuous techniques have the 
potential to extend analgesia but this is at the expense of increased cost, effort, resource utilization and 
potentially increased risk of infection.   
 
The safety of CACNB technique was highlighted by a study by Henningsen et al where no cases of nerve 
injury related to analgesic technique were reported in a series of 97 patients.10  Andersen et al compared 
a CACNB vs control in 40 patients and found that the intervention group reported decreased pain and 
sleep disturbances while retaining the ability to ambulate soon after surgery.11   Mudumbai et al 
evaluated 180 patients undergoing TKA and discovered that continuous adductor canal nerve blockade 
(CACNB) relative to continuous femoral nerve blockade (CFNB) resulted in greater ability to ambulate 
(37 m vs 6 m) on POD 1 and similar pain scores.8  Jaeger et al examined a similar group of 54 patients 
presenting for TKA and found that CACNB relative to CFNB resulted in decreased quadriceps weakness 
and no difference in pain, opioid consumption or weakness.12  Jenstrup et al reported that, compared to 
placebo, CACNB resulted in decreased pain with flexion and opioid consumption.13  Only recently has a 
study comparing SSACNB and SSFNB been published.  This study demonstrated that SSACNB resulted in 
decreased postoperative quadriceps weakness and similar pain control to SSFNB.14  Of interest, previous 
research has demonstrated that 15 ml 0.5% ropivacaine is required to produce ultrasound guided 

 
9 
femoral nerve blockade (including sensory and quadriceps motor weakness) but no such study has yet 
been done for the adductor canal block.15  It is possible that larger volumes of local anesthetic injected 
into the adductor canal could result in proximal spread of local anesthetic and increase quadriceps 
weakness and difficulty ambulating.  It is also possible that decreased volumes of injection may result in 
inferior pain control and difficulties participating in physical therapy. 
1.2 Rationale and hypothesis 
We propose a prospective, single-center, randomized trial to evaluate the impact of volume of injection 
for adductor canal block on patient recovery profile and block characteristics when performed for total 
knee arthroplasty. 
 
2. Objectives 
2.1 Primary outcome and endpoint  
The primary purpose of this study is to compare the patient’s ability to ambulate on POD 1 in patients 
that have received 5, 10 or 20 ml local anesthetic injection for SSACNB.  This will be evaluated by 
determining how quickly a patient is able to ambulate over 10 meters on POD 1 (10 meter walk test). 
 
2.2 Secondary outcomes and endpoints 
The secondary purposes of this study are to compare the following perioperative variables: 
Pre/Intraoperative Variables:   
• 
Opioid consumption 
• 
Sensory blockade 
• 
Patient perceived discomfort with procedure 
• 
Preoperative quadriceps strength 
• 
Preoperative adductor strength 
• 
SF12 mental component and physical component  
• 
WOMAC and Knee Society Score 
• 
UCLA activity score  
• 
Preoperative range of motion  
• 
Degree of varus/valgus deformity. 
 
PACU Variables:   
• 
Pain 
• 
Opioid consumption 
• 
Nausea 
• 
Time in PACU (duration) 
• 
Satisfaction with regional anesthesia 
• 
Location of most severe pain 
 
Floor Variables:   
• 
Pain at rest 
• 
Pain with activity 
• 
Opioid consumption 
• 
Nausea 
• 
Duration of hospitalization 

 
10 
• 
Pain disturbing sleep 
• 
Location of most severe pain 
• 
Satisfaction with regional anesthesia 
 
PT Variables:  
• 
Pain with physical therapy 
• 
Quadriceps strength 
• 
Passive flexion/extension range of motion 
• 
Postoperative quadriceps strength 
• 
Postoperative adductor strength 
 
3. Study design 
This study is a prospective, single-center, randomized trial in which 60 subjects will be enrolled at the 
University of Wisconsin Hospitals and Clinics (UWHC). These subjects must meet study eligibility criteria 
and be scheduled to undergo an elective total knee arthroplasty.  These subjects must also agree to 
undergo neuraxial anesthesia as the primary anesthetic for their surgical procedure and agree to an 
adductor canal block for postoperative analgesia.  Patients will be randomized to receive 5, 10 or 20 mL 
of 0.5% bupivacaine injected into their adductor canal.  Strength following the block and recovery 
characteristics following TKA will then be evaluated including pain, strength and ability to participate in 
physical therapy.   
 
4. Study population 
4.1 Inclusion criteria 
Each patient must meet all of the following inclusion criteria to be enrolled in the study.  
1) The subject is scheduled for elective unilateral TKA 
2) The subject is ≥ 18 years and ≤ 80 years; 
3) The subject’s weight is between 70-120 kg; and 
4) The subject’s primary anesthesia care team has planned for a neuraxial anesthetic (i.e. spinal, 
epidural or combined-spinal epidural). 
5) The patient agrees to receive an adductor canal block. 
6) American Society of Anesthesiologists class 1-3 
 
 
4.2 Exclusion criteria  
Patients meeting any of the following exclusion criteria are not to be enrolled in the study. 
1) Subject is < 18 years of age or >80 years of age; 
2) Subject is non-English speaking; 
3) Subject is known or believed to be pregnant; 
4) Subject is a prisoner; 
5) Subject has impaired decision-making capacity; per discretion of the Investigator 
6) Symptomatic untreated gastroesophageal reflux or otherwise at risk for perioperative aspiration; 
7) Any condition for which the primary anesthesia care team deems neuraxial anesthesia 
inappropriate; 
8) Significant pre-existing neuropathy on the operative limb; 

 
11 
9) Significant renal, cardiac or hepatic disease per discretion of the investigator. 
10) American Society of Anesthesiologists class 4-5 
11) Known hypersensitivity and/or allergies to local anesthetics 
12) Chronic Opioid Use (daily or almost daily use of opioids for > 3 months) 
 
4.3 Protected populations 
Prisoners 
Due to the complexity of state and federal requirements governing the participation of prisoners in 
research, patients who are prisoners will not be considered for participation in this trial. In the unlikely 
event that a subject becomes a prisoner while participating in this trial, study procedures will stop and 
the subject will be returned to the clinical mode used prior to the intervention period or, if desired, a 
ventilator mode requested by the clinical care team. 
 
Pregnancy 
Patients who are known to be pregnant will be excluded from participation. 
 
 
5. Trial interventions 
The intervention portion of this study is the randomized assignment (1:1:1) to receive 5, 10 or 20 ml of 
0.5% bupivacaine, incrementally injected. All studied volumes are well within the acceptable range for 
SSACNB. Randomization will be accomplished using an online service (www.randomizer.org) and 
prefilling sealed envelopes determining each subject’s intervention group.  In all other aspects, the 
subject will receive the standard of anesthesia care appropriate for their surgery or procedure as 
determined by the primary anesthesia team caring for the subject. 
 
5.1 Allocation to intervention 
Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed 
envelope with the group assignment designated within.  Randomization will be accomplished using an 
online service (www.randomizer.org). 
 
Each study subject and the anesthesia team caring for the patient in the operating room will be blinded 
to the study volume the patient received; however, the anesthesia provider performing the block 
(separate from the provider caring for the patient in the operating room) will not be blinded to the study 
volume injected and will have access to all monitors deemed appropriate by the primary anesthesia 
team caring for the subject.  PACU/floor nursing and physical therapy staff will be blinded to volume of 
injection.  The surgery team and study member responsible for pre/postoperative data collection will 
also be blinded to study drug volume. 
 

 
12 
6. Subject recruitment and consent 
6.1 Subject identification and Screening 
The study team will review the medical records of patients scheduled for an elective TKA to check for 
eligibility. Those who appear eligible will receive a phone call from a study team member who is also 
involved in their clinical care 1-7 days prior to their surgery. We will briefly describe the study 
procedures and voluntary nature, and answer any questions they have about it. If the subject is 
interested in participation, they will be instructed to arrive 1 hour earlier than their scheduled surgery 
arrival time so that there is time for consenting, considering participation, and confirming eligibility of 
those who agree to participate. Patients scheduled for an arrival time at or before 8:00 a.m. will not 
eligible for the study.  All protected health information used during the screening process of a potential 
subject will be the minimum necessary for the conduct of this study. Any protected information 
recorded will be destroyed at the end of the screening process.   
 
6.2 Recruitment and consent 
The identified patients will be given written information about the study at the time of check-in for their 
scheduled procedure. Once the anesthesia provider talks with the subject in order to confirm that they 
are a candidate for both spinal anesthesia and an adductor canal block (this conversation is standard 
care),  a research team member will conduct the consent process in the surgery or procedure holding 
area.  In order to ensure the candidate’s privacy and confidentiality, the cubicle’s curtain or room door 
will be closed.  In a tone of voice insufficient for others to overhear the conversation and in the presence 
of only those immediately accompanying the patient and those who are directly involved with the 
patient’s care, the study purpose, procedures, risks, benefits, and alternatives will then be discussed.  
The written information about the study provided to the candidate at the time of their check-in will be 
reviewed and they will be instructed to take as much time as needed to consider participation. While 
any study staff member may conduct the informed consent discussion and obtain informed consent, a 
study physician will be available at all times for any consent-related questions. Any questions that the 
candidate may have will be answered.  Undue coercion will be prevented by stressing that the potential 
subject does not have to agree to participation and that the future care of the potential subject will not 
change regardless of the decision about participation. If the candidate has no further questions and 
would like to participate, they will be asked to sign the written informed consent document.  
 
 
7. Activities and measurements 
 
Prior to the procedure: 
The subject will be met in the preoperative area by a staff anesthesiologist, who interviews and 
examines the subject.  A full explanation of the neuraxial anesthetic and adductor canal block, including 
risks, benefits and alternatives, will be given and informed consent for anesthetic services obtained.  
Quadriceps motor strength and adductor strength will be assessed prior to any nerve blockade.  Muscle 
strength will be assessed with the kiio Sensor (Kiio Inc., Madison, WI USA).  The kiio sensor is a force 
monitoring device that provides objective measurements of patient strength (traditional measurements 
or Manual Muscle Testing typically relies on subjective assessments by medical staff).  To assess the 
subject’s quadriceps and adductor strength, the kiio sensor will be attached to the subject’s ankle or 
upper leg and subject will be asked to forcefully extend the leg at the knee or adduct their leg.  The kiio 
Sensor is not currently commercially available and is currently in the development stage (see attached 
Phase I progress report – APPENDIX D).  A sensory exam of the leg (temperature and pinprick) will also 

 
13 
be conducted prior to nerve blockade to determine baseline sensation of femoral, obturator and lateral 
femoral cutaneous nerves.  For these tests, the jagged edges of a broken tongue depressor and alcohol 
swab will be used to produce pinprick and cold sensation.  Subjects will be asked to report if sensation is 
normal, absent or decreased to both pinprick and cold.   
From the subject’s medical record the SF12 mental component and physical component, WOMAC and 
Knee Society Score, UCLA activity score, preoperative range of motion and degree of varus/valgus 
deformity will be collected.  These scores and procedures are standard of care for all patients 
undergoing a TKA. 
 
Adductor Canal Block Procedure:  
An intravenous catheter will be placed, the subject will be transported to the block room or another 
room appropriate for provision of regional anesthesia and the subject will be pre-medicated with 
midazolam and/or fentanyl as needed at the discretion of the staff anesthesiologist.   
 
Adductor canal blockade will be performed with the assistance of ultrasound guidance following 
sedation with midazolam and fentanyl as deemed appropriate by the staff anesthesiologist.  The 
adductor canal will be located in a mid-thigh position.  A Stimuplex needle (B. Braun Medical Inc., 
Melsungen, Germany) will be inserted in-plane to the ultrasound probe until the tip of the needle is 
appropriately positioned.   
 
Study Randomization:  
Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 
ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will 
be determined by opening a sequential, pre-sealed envelope with the group assignment designated 
within. All studied volumes are well within the acceptable range for SSACNB. 
 
15 minutes post-block placement: 
A sensory examination will be done 15 minutes following adductor canal block with pin prick (sharp end 
of tongue depressor broken in two) and alcohol swab in distribution of femoral, obturator and lateral 
femoral cutaneous nerve.  Motor examination of quadriceps and adductor strength will also be tested 
15 minutes following adductor canal blockade.    
 
During the Surgical Procedure: 
Neuraxial anesthesia will be performed as normally accomplished prior to initiation of the surgical 
procedure.  Generally, this involves the administration of a combined-spinal-epidural anesthesia with 
2.5 – 3 ml 0.5% bupivacaine administered into the intrathecal space.    
 
In the operating room and procedural suite, monitors will be applied to the subject per established 
American Society of Anesthesiology (ASA) guidelines.  At a minimum, these include non-invasive 
monitoring of blood pressure by automated cuff, oxygen saturation via pulse oximetry, heart rate and 
rhythm by 3-lead continuous electrocardiographic (ECG) tracing, core body temperature and expired 
carbon dioxide concentration.  Additional monitoring may be applied on a case-by-case basis as deemed 
appropriate by the attending anesthesiologist.  Ongoing sedation with midazolam, fentanyl and propofol 
will be provided as deemed appropriate by the staff anesthesiologist.  
 
The surgical team will inject 50 ml 0.125% bupivacaine with 30 mg ketorolac (when deemed to be 
clinically appropriate) into the joint and posterior knee at the conclusion of the surgical procedure. 
 

 
14 
Post-Procedure:  
The patient will be visited in the PACU to assess pain, opioid consumption, nausea, duration of PACU 
stay, satisfaction with regional anesthesia technique and location of most severe pain. This information 
will be ascertained by questioning the patient and reviewing the subject’s medical record.  Many of 
these assessments are routinely done as standard of care at the current time. 
Postoperative analgesia will generally consist of scheduled toradol, scheduled Tylenol, MS Contin or 
Oxycontin, oxycodone PRN, and celebrex 100-200 mg BID or any combination of these.  Therapy may be 
altered for patients with history of drug intolerances or allergies or any other contraindication to a 
specific therapeutic agent.  Extended release opioid therapy may also be excluded in select elderly 
patients at the discretion of the orthopedic team.  This therapy represents standard of care and is not 
altered by study involvement. 
 
24 and 48-hours post-operative Follow-up: 
The patient will be assessed on the floor for pain at rest, pain with activity, opioid consumption, nausea, 
pain disturbing sleep, location of most severe pain and satisfaction with regional anesthesia technique 
will be ascertained at 24 and 48 hours following the surgical procedure by questioning patient and 
review of medical record.  Pain with be assessed using a Numerical Rating Scale (NRS) (0-10) where 0 
represents no pain and 10 represents the worst pain imaginable.  Duration of hospitalization will be 
obtained from review of medical record. Subjects with new or persistent complaints at 48 hours post-
surgery that could be related to the study procedures will be offered continued follow-up by telephone 
or in-hospital room visit until the complaints resolve. Follow-up procedures would depend greatly on the 
clinical presentation but could include imaging, specialist consultation or surgical intervention. Subjects 
without complaints will be given appropriate information for contacting the research team if such 
complaints arise. 
 
Physical therapy will determine pain with physical therapy, quadriceps strength, passive 
flexion/extension range of motion, postoperative quadriceps strength, postoperative adductor strength, 
and 10 meter walk test (gait velocity) at 24 and 48 hours postoperatively.  All measurements of strength 
will be done using the Kiio Sensor. Based on physical therapy team experience, patients are currently 
able to ambulate 10 meters in approximately 45 seconds on postoperative day one with 20 ml of local 
anesthetic injected into the adductor canal.  The physical therapy team feels that ambulation velocity is 
generally limited by weakness and pain.  However, we do not currently know if decreasing the dose of 
local anesthetic injected into the adductor canal will result in improved ambulation resulting from 
increased strength or worsened ambulation performance secondary to increased pain.  
 
Concomitant Medications:  
Analgesic and anti-emetic requirements for block placement, intraoperatively, in PACU, at 24 hours, 48 
hours and during course of hospitalization will be extracted from the patient’s electronic medical record. 
 
7.1 Data entry 
Information extracted from the subject’s medical records includes date of service, subject name, date of 
birth, medical record number, age, gender, height, weight, data pertaining to the subject’s pain, opioid 
consumption and ASA classification.  In addition, SF12 mental component and physical component, 
WOMAC and Knee Society Score, UCLA activity score, preoperative range of motion and degree of 
varus/valgus deformity will be collected from the medical record. 
 

 
15 
All study data will be collected by a study team member on a standardized case report form (CRF) (see 
Appendix B) and transferred to an electronic Microsoft Excel spreadsheet suitable for export in coded 
format to a statistical analysis program.  Data entry into electronic format will take place on a private 
computer away from potential viewing by non-study personnel.  The paper and electronic data will be 
kept in the primary investigator’s locked office in the Department of Anesthesiology.  The computer will 
be pass-coded and linked to a secure Anesthesia Department server to allow access only to approved 
study personnel.  At the end of seven years, all identifiable data will be destroyed as required by UWHC. 
 
7.2 Subject withdrawals 
At any point prior to or during the intervention period, the subject’s clinical care team or a study 
physician may decide the subject should be withdrawn from the study. If a subject is withdrawn from 
the study for any reason the subject will then be followed according to the standard of care follow-up 
plan. 
 
Study intervention will immediately stop and subject’s clinical care team and a study physician will be 
immediately notified if one of the following occurs: 
1) The subject suffers a severe adverse perioperative outcome that precludes participation in 
physical therapy or measurements of motor strength or sensory examination  
 
In the event the study method is terminated, the reason for termination will be documented on a case 
report form.   
 
 
8. Data analysis and statistical considerations 
 
All data will be summarized using standard descriptive statistics, including mean, standard deviation, 
minimum, maximum, median, inter-quartile range, and confidence intervals, as appropriate.  The data 
will be presented graphically (where possible) using scatter plots, profile plots, or histograms.  Data 
analyses will be performed on an intent-to-treat basis using SAS (SAS Institute Inc., Cary, NC; version 8.2 
or greater) or Minitab (Quality Plaza, State College, PA; version 13.0 or greater).  The primary analyses 
will consist of comparing the three study volumes of injection for superiority.  For all tests, statistical 
significance will be defined as a p-value less than 0.05.  ANOVA and two-sample t-test will be used to 
compare the data between the three groups or between any two individual groups.  Repeated measures 
ANOVA will be used to analyze multiple follow-up data points.  Patients with missing longitudinal data 
will be handled by either using data imputation methods to replace the missing data or via the use of 
repeated measures ANOVA to better approximate the average values at each time point.  Bonferroni 
correction will be utilized to counteract the problem of multiple comparisons and control the familywise 
error rate. 
 

 
16 
8.1 Sample size determination 
This study is a randomized, three group (5, 10, 20 ml bupivacaine), mixed study using the primary 
endpoint of ambulation or gait velocity over 10 meters (10 meter walk test) on POD 1.  The data from 
this preliminary study will be used to generate hypotheses for future trials.  We performed an effect size 
calculation based on the ratio of the hypothesized differences and the standard deviation based on our 
current experience.   Based on physical therapy team experience, patients are currently able to 
ambulate 10 meters in approximately 45 seconds on postoperative day one with 20 ml of local 
anesthetic injected into the adductor canal.  The physical therapy team feels that ambulation velocity is 
generally limited by weakness and pain.  However, previous retrospective research done at our own 
institution demonstrated that adductor canal block patients were able to ambulate more effectively 
than those patients receiving a femoral nerve catheter (i.e. those with a more profound motor 
blockade).  We therefore hypothesize that decreasing the dose of local anesthetic delivered into the 
adductor canal will decrease the amount of time required to ambulate 10 m and that this difference 
could approach 15 seconds.  We hypothesize that the standard deviation may be of similar magnitude.  
With a power of 0.8 and significance level of 0.05, 16 patients are required per group.  Increasing 
enrollment to 20 patients per group will allow for patient drop out.  
 
 
9. Risks and benefits of trial participation 
 
9.1 Potential risks 
It is possible that larger volumes of local anesthetic could track proximally within the adductor canal and 
result in significant motor weakness to the quadriceps muscle.  Significant weakness may be a risk factor 
for falls.  It is also possible that decreased volumes may result in increased pain and difficulty 
participating with physical therapy.  Inherent risks associated with nerve blockade include bleeding, 
infection, nerve damage, allergic reaction to local anesthetic, etc.  However, standard of care is currently 
for patients presenting for TKA to receive an adductor canal block and therefore these would not 
represent additional risks.     
 
Risks associated with loss of confidentiality 
There is a risk that information recorded about subjects will be shared with people who would not 
normally have access to this information.  
 
Unknown risks 
This study may involve risks to the subject which are currently unforeseeable. We will inform subjects as 
soon as possible if we discover any information that may affect the subject's health, welfare, or decision 
to be in this study. 
 
 
9.2 Mitigation of potential risks 
The risk of increased quadriceps weakness and fall will be minimized by the involvement of physical 
therapists for all postoperative motor strength evaluations.  The risk of inadequate analgesia will be 
minimized by the availability of supplemental oral and potentially intravenous analgesics.    
 
 

 
17 
9.3 Potential benefits and risk-to-benefit ratio 
While there are risks to involvement in this research trial, they generally should be infrequent and not 
difficult to manage.  The potential benefits of this research could result in quicker hospital discharge 
time with resulting decreases in costs.  Patients may also benefit from a decreased risk of infection if 
they are able to leave the hospital sooner or improved implant function if early postoperative 
rehabilitation is optimized. 
 
10. Adverse events and unanticipated problems 
 
10.1 Adverse event definitions 
 
Adverse event (AE) 
An adverse event is defined as any untoward or unfavorable medical occurrence in a human subject 
including any abnormal sign, symptom, or disease temporally associated with the SSACNB or study 
procedure that appears or worsens during the study or study follow-up period.  AEs may be anticipated 
(e.g., redness/soreness at injection site) or unanticipated (e.g., bleeding/infection/nerve damage).  
Adverse event information will be collected throughout the study from informed consent through 
resolution of the AE and documented on the case report form or the standard follow-up questionnaire.   
 
All AEs (anticipated and unanticipated) will be recorded on one of the study data sheets (case report 
form or standard questionnaire) by a study investigator or study staff.  In the event of an unanticipated 
AE, the primary anesthesia team caring for the subject will intervene as deemed appropriate.  These are 
the same provisions that would be made for any non-study case and represents standard practice. 
 
Serious adverse event (SAE) 
A serious adverse event is defined as any adverse event that meets one of the following criteria: 
• Results in death; OR 
• Is life-threatening; OR 
• Requires hospitalization or prolongs existing hospitalization; OR 
• Results in significant or persistent disability or incapacity; OR 
• Results in a congenital anomaly/birth defect 
 
Given the minimal risk associated with the use of SSACB and the study procedures, no serious adverse 
events (SAEs) are anticipated. If a SAE occurs, the study primary and co-primary investigators will be 
immediately notified and further enrollment in the study will be halted until a full explanation of the 
cause of the event and its relationship to the SSACB and/or study procedure is understood.  The IRB will 
be notified and re-initiation of study enrollment will not occur until approved by the IRB. 
 
Unanticipated problem (UP) 
An unanticipated problem is defined as an event that meets all of the following criteria: 
1) Unexpected in severity, nature, or frequency given the research procedures and the 
characteristics of the subject population (i.e., problems that are not described in this protocol or 
other study documents); AND 
2) Related or possible related to participation in the research; AND 
3) Suggests that research places subjects or others at a greater risk of harm related to the research 
than was previously known or recognized.  

 
18 
 
10.2 Severity assessment 
The severity of all adverse events will be assessed according to the following scale: 
• Mild = not requiring treatment or intervention 
• Moderate = resolved with treatment/intervention 
• Severe = inability to carry on normal activities and required professional medical attention 
 
10.3 Causality assessment 
The Site PI will determine the relationship of adverse events to the research intervention using the 
following scale: 
• Definite = AE is clearly related to the study procedures 
• Probable = AE is likely related to the study procedures 
• Possible = AE is possibly related to the study procedures 
• Unlikely = AE is doubtfully related to the study procedures 
• Unrelated = AE is clearly not related to the study procedures 
 
Additionally, AEs will be considered “probably related” to study procedures if one of the following 
happens: 
• Fall; OR 
• Local anesthetic toxicity or allergy 
 
10.1. 
Procedures for recording and reporting adverse events 
All serious adverse events that occur from the time the subject provides informed consent through and 
including 28 calendar days after the procedure will be recorded. Non-serious adverse events that occur 
from the time the study procedures begin to the end of the last study visit will be recorded.  
 
10.4 Other reportable events 
Reporting timeframes begin when the site learns of the occurrence of the event.  
 
Event 
Definition 
Reporting  
Breach of 
confidentiality 
The exposure of any study information or 
communications directly related to a study 
subject to anyone not named as study staff or the 
release of a study subject’s identifiable 
information to study staff who were not specified 
to receive such information in the protocol or IRB 
application.  
Treat as major deviation 
(below) 
Protocol 
deviation 
A deviation is an incident involving a departure 
from the IRB-approved protocol in the actual 
conduct of the study. Deviations may result from 
the action of the participant, investigator, or 
staff. 
See below 

 
19 
Event 
Definition 
Reporting  
Major 
deviations 
Deviations are considered major when the 
unapproved change(s) in previously approved 
research activities, implemented without IRB 
approval, may potentially adversely affect 
subjects’ rights, safety, welfare, or willingness to 
continue participation, or affect the scientific 
design of the study and/or the integrity of the 
resultant data. 
Treat as an Unanticipated 
Problem (above) 
Minor 
deviations  
Deviations are considered minor when the 
unapproved change(s) in previously approved 
research activities, implemented without IRB 
approval, do not adversely affect subjects or the 
integrity of the study data. 
Sites are to report cumulative 
events to AE Coordinator at 
time of continuing review.  
Protocol 
violation 
An incident involving an intentional deviation 
from the IRB-approved protocol that was not 
implemented in response to an emergency 
situation and that may impact a subject’s rights, 
safety, and/or welfare, makes a substantial 
alteration to risks to subjects, or affects the 
scientific design of the study and/or the integrity 
of the resultant data. Violations may also be 
repeated deviations (major or minor) of the same 
nature. Violations can represent serious or 
continuing non-compliance with the federal 
regulations and guidelines for ethical conduct of 
human subject research. 
Treat as an Unanticipated 
Problem (above) 
Protocol 
Exceptions 
A protocol exception is an IRB-approved 
deviation for a single subject or a small group of 
subjects, but is not a permanent revision to the 
research protocol. 
Protocol exceptions must be 
approved by local IRB prior to 
implementation. 
 
11. Trial safety monitoring  
 
11.1 Data Safety Monitoring Committee 
 
After 15 subjects have been recruited, the study data will be reviewed by an independent 
anesthesiologist, blinded to study arm assignment, to ensure that no safety concerns exist.  In the 
unlikely event that there is a safety concern, study recruitment will be halted and an independent Data 
Safety Monitoring Committee (DSMC), consisting of a minimum of three qualified practitioners, will be 
convened to evaluate the safety concern and make recommendations regarding changes to the study 
methods or termination of the study. 
 

 
20 
12. Administrative requirements 
12.1 Good clinical practice 
The study will be conducted in accordance with FDA and ICH guidelines for Good Clinical Practice. All 
study staff will be thoroughly familiar with the contents of this protocol and associated trial materials. 
 
12.2 Data quality assurance 
Paper records containing personal identifying information will be stored in the study primary 
investigator’s locked office and destroyed after seven years as required by UWHC. 
 
12.3 Study monitoring 
After 30 subjects have been recruited, the study data will be reviewed by an independent 
anesthesiologist, blinded to study arm assignment, to ensure that no safety concerns exist.  In the 
unlikely event that there is a safety concern, study recruitment will be halted and an independent data 
safety board, consisting of a minimum of three qualified practitioners, will be convened to evaluate the 
safety concern and make recommendations regarding changes to the study methods or termination of 
the study. 
 
12.4 Ethical consideration 
The study will be conducted in accordance with ethical principles founded in the Declaration of Helsinki. 
The IRB will review all appropriate study documentation in order to safeguard the rights, safety and 
well-being of the subjects. The study will only be conducted at sites where IRB approval has been 
obtained. The protocol, informed consent form, written information given to the patients, safety 
updates, annual progress reports and any revisions to these documents will be provided to the IRB by 
the investigator.  
 
12.5 Patient confidentiality 
 Subject privacy and confidentiality will be ensured by restricting access to personal identifying study 
data only to members of the research team.  In addition, as mentioned previously, recruitment will take 
place in the subject’s cubicle or room in the preoperative or preprocedural holding area with the curtain 
drawn or door closed, in a tone of voice insufficient for others to overhear the conversation and in the 
presence of only those immediately accompanying the subject and those who are directly involved with 
the subject’s care.   
 
12.6 Investigator compliance 
The investigator will conduct the trial in compliance with the protocol approved by the IRB. Changes to 
the protocol will require written IRB approval prior to implementation, except when the modification is 
needed to eliminate an immediate hazard(s) to subjects.  
 

 
21 
12.7 Subject cost and payment 
Cost  
Subjects will not incur additional costs due to their participation in this study. 
 
Payment 
Subjects will not be paid for participation in this study. 
13. Funding sources 
Funding will be provided by the Department of Anesthesiology’s Research and Development (R&D) 
Committee.  
 
14. Publication Policy 
 
 
References 
1. Kardash K, Hickey D, Tessler MJ, Payne S, Zukor D, Velley AM.  Obturator versus femoral nerve 
block for analgesia after total knee arthroplasty.  Anesth Analg 2007;105:853-858. 
2. Macalou D, Trueck S, Meuret P, Heck M, Vial F, Ouologuem S, Capdevila X, Virion JM, Bouaziz H.  
Postoperative analgesia after total knee replacement: the effect of an obturator nerve block 
added to the femoral 3-in-1 nerve block.  Anesth Analg 2004;99:251-254. 
3. McNamee DA, Parks L, Milligan KR.  Post-operative analgesia following total knee replacement: 
an evaluation of the addition of an obturator nerve block to combined femoral and sciatic nerve 
block.  Acta Anaesthesiol Scand 2002;46:95-99. 
4. Bergeron SG, Kardash KJ, Huk OL, Zukor DJ, Antoniou J.  Functional outcome of femoral versus 
obturator nerve block after total knee arthroplasty.  Clin Orthop Relat Res 2009;467:1458-1462. 
5. Sato K, Sai S, Shirai N, Adachi T.  Ultrasound guided obturator versus sciatic nerve block in 
addition to continuous femoral nerve block for analgesia after total knee arthroplasty.  Japanese 
Clinical Medicine 2011;2:29-34.  
6. Kapoor R, Adhikary SD, Siefring C, McQuillan PM.  The saphenous nerve and its relationship to 
the nerve to the vastus medialis in and around the adductor canal: an anatomical study.  Acta 
Anaesthesiol Scand 2012;56:365-367. 
7. Saranteas T, Anagnostis G, Paraskeuopoulos T, Koulalis D, Kokkalis Z, Nakou M, 
Anagnostopoulou S, Kostopanagiotou G.  Anatomy and clinical implications of the ultrasound-
guided subsartorial saphenous nerve block.  Reg Anesth Pain Med 2011;36:399-402. 
8. Mudumbai SC, Kim E, Howard SK, Workman JJ, Giori N, Woolson, Ganaway T, King R, Mariano 
ER.  Continuous adductor canal blocks are superior to continuous femoral nerve blocks in 
promoting early ambulation after TKA.  Clin Orthop Relat Res 2013 Epub. 
9. Kwofie MK, Shastri UD, Gadsden JC, Sinha SK, Abrams JH, Xu D, Salviz EA.  The effects of 
ultrasound-guided adductor canal block versus femoral nerve block on quadriceps strength and 
fall risk.  A blinded, randomized trial of volunteers.  Reg Anesth Pain Med 2013;38:321-325. 
10. Henningsen MH, Jaeger P, Hilsted KL, Dahl JB.  Prevalence of saphenous nerve injury after 
adductor-canal-blockade in patients receiving total knee arthroplasty.  Acta Anaesthesiol Scand 
2013;57:112-117.  

 
22 
11. Andersen HL, Gyrn J, Moller L, Christensen B, Zaric D.  Continuous saphenous nerve block as a 
supplement to single-dose local infiltration analgesia for postoperative pain management after 
total knee arthroplasty.  Reg Anesth Pain Med 2013;2:106-111. 
12. Jaeger P, Zaric D, Fomsgaard JS, Hilsted KL, Bjerregaard J, Gyrn J, Mathiesen O, Larsen TK, Dahl 
JB.  Adductor canal block versus femoral nerve block for analgesia after total knee arthroplasty.  
A randomized, double-blind study.  Reg Anesth Pain Med 2013;38:526-532. 
13. Jenstrup MT, Jaeger P, Lund J, Fomsgaard JS, Bache S, Mathiesen O, Larsen TK, Dahl JB.  Effects 
of adductor-canal-blockade on pain and ambulation after total knee arthroplasty: a randomized 
study.  Acta Anaesthesiol Scand 2012;56:357-364. 
14. Kim DH, Goytizolo EA, Kahn RL, Maalouf DB, Manohar A, Pattt ML, Goon AK, Lee YY, Ma Y, 
YaDeau JT.  Adductor canal block versus femoral nerve block for total knee arthroplasty.  A 
prospective, randomized, controlled trial.  Anesthesiology 2014;120:540-550. 
15. Casati A, Bariarello M, Di Cianni S, Danelli G, De Marco G, Leone S, Rossi M, Fanelli.  Effects of 
ultrasound guidance on the minimum effective anaesthetic volume required to block the 
femoral nerve.  British J of Anaesh 2007;98:823-827. 
16. Maffiuletti NA.  Assessment of the hip and knee muscle function in orthopaedic practice and 
research.  J Bone Joint Surg Am 2010;92:220-229. 

 
23 
Appendix D – Kiio Information Sheet 
 
Kiio Inc. began the Phase I “WiFi-enabled hand-portable real-time force sensor to objectively assess 
strength” project on March 1, 2013, and concluded the project August 1, 2013. (Expenditures prior to 
March 1, 2013 were borne by Kiio.) This is the final summary report for the Phase I project. Kiio 
successfully completed all Phase I Aims. No changes were made to the project’s goals and aims as 
outlined in the original Phase I Research Strategy. 
The overall project goal of Phase I was to refine, miniaturize, and test a clinically relevant prototype 
device (the kiio™) that would be able to accurately and consistently measure force over time so as to 
provide kinetic measurement of muscle strength, continuously tracking variability in strength over the 
entire range of movement to enable a complex analysis of muscle performance. Our goals for the kiio 
were that it should (1) provide wireless data output via proprietary software to PCs in real-time, allowing 
a clinician to track and interpret data as the patient generates it; (2) offer high inter-rater reliability for 
consistency between clinicians; (3) interface with commonly used rehabilitative equipment such as 
resistance cables; (4) be hand-portable, not requiring dedicated clinic space; (5) be cost effective in terms 
of initial investment and clinician training; and (6) be rugged enough to withstand the rigors of daily use 
while maintaining accuracy. Its clinical significance would be to provide a fast, objectively valid, reliable, 
portable and cost-effective method of strength assessment, thus eliminating a significant barrier to the 
implementation of evidence-based evaluation and outcome measurement in prescriptive rehabilitative 
exercise.  
Aim 1: Develop and prototype a functional, integrated kiio to measure continuous muscle force 
output and translate this information to a real-time digital data stream. Kiio began with a high-level, 
logical engineering model of the device in block diagrams depicting a device 
able to generate force readings using off-the-shelf components and proprietary 
software. We developed an electrical and logical design for a printed circuit 
board (PCB) using Computer assisted engineering software (CAE). We created 
protocols to test the PCB design and identify and remove errors, while keeping 
functional design elements. Successive iterations eliminated design errors and 
added functionality, leading to a stable design. We wrote firmware (hard-coded 
proprietary programming) to control the microprocessor, and synchronized the 
WiFi transceiver and a wireless router to ensure the proper communication 
between the kiio and a PC, necessary to display data in real-time. 
Figure 1 

 
24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Phase I, Aim 1 outcomes 
Task 
Objective outcomes/Milestones 
Result 
1.1 
Hand-portability: kiio prototype will be no larger 
than 7 x 4 x 10 cm and no heavier than 150 g. 
Success. kiio weighs just 120g and measures  
7cm wide x 9cm high x 4cm deep (see Figure 1) 
1.2 
Design elements: kiio prototype will include:  
a) a strain gauge, b) a microprocessor, c) a wireless 
WiFi transmitter, and d) an Li-ion battery 
Success. kiio includes a strain gauge, microprocessor, 
wireless WiFi transmitter and a rechargeable Li-ion 
battery 
1.3 
Integration with commonly-used rehabilitative 
exercise equipment: kiio prototype will connect to 
a variety of commonly used resistance 
mechanisms 
Success. kiio connects directly to commonly-used 
resistance mechanisms such as elastic cables, straps, 
and portable handles (see Figure 2) 
1.4 
WiFi data delivery: kiio prototype will send a 
continuous, real-time digital WiFi data stream to a 
PC 
Success. kiio sends a continuous, real-time digital data 
stream wirelessly over WiFi of force readings over time 
to a computer as described and tested in Aims 2 & 3 

 
25 
Aim 2: The kiio prototype will be iteratively calibrated to ensure that it 
properly reads known force and can be set to ignore a tare weight. The kiio 
requires calibration for precision and consistency; without it, accuracy and test-
retest reliability would be jeopardized. Kiio used a six step process (Figure 3) to 
facilitate this Aim. Ensuing 
successful completion of the 
setup steps, we tested 10 devices 
by repeatedly hanging the 20 
plates (one at a time) on each 
device. With each additional 
plate the weight was allowed to 
settle and kiio reported a static 
force reading to the PC where it 
was recorded. Cumulative 
readings of these weights were 
also taken using a commercially available load cell for comparison.  
Summary of Test Results: All ten devices were initially calibrated and had tare 
weights set. Nine out of ten devices were accurate to within 2% (1.0 lb) on the 
first pass (i.e., without the need for a re-calibration or re-tare). Their average 
deviation from the load cell ranged from 0.11 lbs. to 0.83 lbs. with no readings 
deviating from expected results by more than 1.0 lb. Only one device (#7E) 
exceeded our target tolerance, with an average under-weight of 1.18 lbs. per 
reading. The readings from device #7E were consistently low. Consequently, the device was re-calibrated, 
re-tared, and the tests were rerun and kiio #7E yielded an average deviation of 0.14 lbs. from the expected 
results (see Table 3). The initial readings of device #7E suggests that our technician did not properly do a 
full tare (step #6 above) prior to conducting tests. 
Table 4 – Phase I, Aim 2 outcomes 
Tas
k 
Objective outcomes/Milestones 
Result 
2.
1 
kiio will correctly measure force 
and transmit accurate data within 
the larger of either 2% absolute 
error or 1 lb. 
Success. Kiio extended the number of test kiio devices from 4 to 
10. All devices successfully completed calibration on their first 
attempt, and 100% of the force readings were within acceptable 
tolerance. 
2.
2 
Redefine of zero point: kiio 
prototype will be able to accept a 
constant offset and thereby 
redefine the zero point, or a given 
tare weight. 
Success. A connector was hung from the device and an offset 
was sent from the PC to the kiio to tare the weight back to 0.0 
lbs. 100% of devices were successful. This process was repeated 
with various connectors, ranging in weight from 0.2 lbs. to 5.1 
lbs. Again, 100% of devices were successful in the tare process. 
2.
3 
Maximum static weight: kiio 
device will be able to accurately 
register static weights from 0.0 to 
100.0 lbs.  
Success. The commercial load cell registered a total of 103.1 lbs 
(99.7% accurate, with possible variability derived from 
cumulative rounding error over 20 plates). 9 of the 10 kiio 
devices were accurate to within tolerance on the 1st attempt (i.e., 
without a need for re-calibration). 100% of kiios met 
specification after recalibrating and re-taring one device (#7E). 
Figure 3 -  Steps to prepare kiio for static testing
1
Establish two sets of known weights
a
Kettlebells for creating callibration curves
b
~5 lb. plates for static device testing
2
Create calibration software for kiio
3
Establish callibration equation for each device
4
Calibrate kiio by loading equation into device memory
5
Create Tare (Zero-out) software for kiio
6
Tare kiio by loading offset into device memory
Action
Step
Load 
Cell
Kiio 
#7E
Delta
0.1
0.3
0.2
5.1
5.2
0.1
10.3
10.3
0.0
15.2
15.0
-0.2
20.7
20.4
-0.3
25.8
25.7
-0.1
30.8
30.9
0.1
35.8
36.4
0.6
40.9
41.4
0.5
46.0
46.3
0.3
51.3
51.6
0.3
56.0
56.6
0.6
61.0
61.5
0.5
66.2
66.4
0.2
71.3
71.4
0.1
76.4
76.6
0.2
81.3
81.6
0.3
86.5
86.6
0.1
92.1
92.1
0.0
97.4
97.1
-0.3
103.1
102.8
-0.3
Table 3 - Device 
Results

 
26 
Aim 3: Verify the prototype measurements are valid and reliable over high use and extended 
sessions. The kiio device must be used rigorously over a high number of repetitions to ensure it maintains 
accuracy and reliability in order to provide valid and consistent measurements through expected durations 
of use. The aim contained two stages: (1) Compare the kiio to a calibrated strain gauge for consecutive 
cycles to analyze statistical variances; and (2) examine accuracy after 20 
days of use. 
Kiio created a motorized test fixture (Figure 4) to exercise 6 devices with 
a series of cyclical tests. Testing software was used to collect force 
readings from kiio devices and a commercial load cell. Data was plotted 
in real-time to the screen, as well as logged to a Microsoft Access 
database 
for 
further 
analysis in 
Microsoft 
Excel. 
Test 
#1 was to 
run 
each 
device through a series of ~500 
cycles of 
applying a force up to a threshold 
and then 
relaxing that force back to a lower limit. Peak values from the kiio for each cycle was analyzed against 
the peak values from the load cell. 100% of the kiios were within this Aim’s accuracy threshold for 100% 
of these cycles. 
Additional analysis of the full 33,000+ samples per device (beyond the scope of the original Aim), 
demonstrated that the device not only reports peak forces accurately during dynamic use, but tracks well 
throughout the entire force curve. Figure 5 is a close-up of data from a kiio device (shown in green) 
plotted against the load cell (in red). The graph shows that as forces range from 8-36 lbs., the kiio tracks 
the commercial load cell with amazing accuracy. Figure 6 shows, for each device, the # of cycles tested 
and the linear regression analysis R2 and ICC statistics. A typical scatter plot and residual plot is also 
shown. 
Kiio also conducted multiple tests to determine if readings drift over time. In addition to the specified 20 
days of dynamic load testing for durations ranging from 10 minutes to 1 hour, we also performed static 
weights tests 3 months after the device’s original calibration. Our conclusion: there’s no discernible drift 
after 3 months of use. Figure 7 is a summary of statistics for the 20-day testing on 4 kiio devices: 
Figure 4 
Device 
ID
Cycles
R2
ICC(3,1)
95% CI
60
504
0.98
0.989
0.987-0.990
67
500
0.99
0.995
0.995-0.996
69
500
0.99
0.994
0.993-0.995
6D
500
0.99
0.995
0.994-0.996
75
493
0.99
0.993
0.992-0.994
7E
501
0.99
0.996
0.996-0.997
Figure 6  
Figure 5 

 
27 
 
Table 5 – Phase I, Aim 3 outcomes 
Tas
k 
Objective outcomes/Milestones 
Result 
3.
1 
Measurement validity: kiio prototype will 
accurately measure forces over time as 
compared to industry calibrated strain gauge 
(with no more than 2% absolute error, and 
R²≥0.98) over the course of 500 cycles. 
Success. 6 out of 6 devices passed this test with 
100% of samples taken within this specified 
tolerance (2998 peak readings from the kiio 
devices were within 1.0 lb. of the load cell value). 
The R2 and ICC numbers also verify the accuracy 
of the kiio device. 
3.
2 
Reliability: kiio prototype will demonstrate 
high intra-class correlation coefficients 
(ICC≥0.99) comparing baseline to tests that 
recur over time, throughout extended testing 
periods (10 min. - 1 hr. continuous use) 
Success. The results of dynamic testing produced 
the same consistency that static testing exhibited: 
All readings were within the tolerance of this Aim; 
kiio is ready to be ruggedized and enter the next 
phase of testing. 
Kiio has shown prototype kiio devices provide accurate measurements for thousands of use cycles over 
the course of weeks of continuous use, and that the kiio is capable of use with similar frequency to 
manual muscle testing in a typical physical therapy clinic by one therapist over the course of a month with 
no loss of accuracy. 
Successful Completion: By successfully completing all of the Aims set forth in Phase I, Kiio has 
demonstrated the feasibility of a hand-portable wireless kiio device prototype. kiio provides objectively 
valid, reliable measurements of force over time, and accurately transmits this data wirelessly to a PC. This 
is a major step in Kiio’s overall vision of developing the integrated kiio FLEX System: combining the 
kiio device and kiio FLEX software for Physical and Occupational Therapists (PT/OT’s). In Phase II Kiio 
proposes to further refine and ruggedize the kiio for clinical use, to develop kiio FLEX, create an 
integrated animated exercise library, and to test the system in clinical settings. Concurrently, we will be 
completing 510k premarket notification on the kiio FLEX System. The fully developed kiio FLEX 
System will be positioned to provide PT/OT’s a fast, objectively valid, reliable, portable and cost-
effective method of strength assessment. This will enable PT/OT’s to integrate evidence-based 
assessments into their practices which could significantly reduce the disability burden on the U.S. 
population (both individual and societal costs) by enhancing clinical efficiency and increasing positive 
patient outcomes.  
 
Figure 
R2
ICC(3,1)
95% CI
R2
ICC(3,1)
95% CI
60
0.97
0.982
0.973-0.988
0.98
0.99
0.985-0.993
67
0.97
0.985
0.977-0.990
0.98
0.988
0.982-0.992
69
0.98
0.992
0.988-0.995
0.99
0.995
0.993-0.997
7E
0.99
0.995
0.993-0.997
0.99
0.989
0.983-0.992
Day 1
Day 20
Device 
ID